Cargando…
OC.06.7 LOWER INCIDENCE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH NON-GUT SELECTIVE BIOLOGIC THERAPY
Autores principales: | Ferretti, F., Cannatelli, R., Monico, M.C., Carvalhas Gabrielli, A.M., Carmagnola, S., Maconi, G., Ardizzone, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451187/ http://dx.doi.org/10.1016/S1590-8658(21)00526-0 |
Ejemplares similares
-
OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME
por: Marasco, G., et al.
Publicado: (2023) -
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021) -
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
por: Ferretti, Francesca, et al.
Publicado: (2022) -
Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge
por: Ferretti, Francesca, et al.
Publicado: (2023) -
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
por: Ferretti, Francesca, et al.
Publicado: (2022)